Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study
-
By
-
Emma Birnie
-
Magda Vergouwe
-
Brent Appelman
-
Jason J Biemond
-
Jarom Heijmans
-
Brooke E Nichols
-
W Joost Wiersinga
-
Stephanie Popping
-
on behalf of
-
the TURN-COVID studygroup
-
Matthijs R A Welkers
-
Hans L Zaaijer
-
Frans J van Ittersum
-
Maarten F Schim van der Loeff
-
Marije K Bomers
-
Marie José Kersten
-
Mette D Hazenberg
-
Marc van der Valk
-
E Marleen Kemper
-
Frits R Rosendaal
-
Mark G J de Boer
-
Renée A Douma
-
Marcel van den Berge
-
Robert-Jan Hassing
-
Heidi S M Amerlaan
-
Marit G A van Vonderen
-
Janneke E Stalenhoef
-
Robin Soetekouw
-
Frank van de Veerdonk
-
Marvin A H Berrevoets
-
Robbert J van Alphen
-
Frits van Osch
-
Jiri F P Wagenaar
-
Rob J van Marum
-
Astrid M L Oude Lashof
-
Cees van Nieuwkoop
-
Eliane M S Leyten
-
Hazra S Moeniralam
-
Joost N Vermeulen
-
March 26, 2025
-
0 min
Top Institutions in Infectious Disease
Brief introduction explaining scope and methodology.
-
#1
Harvard T.H. Chan School of Public Health
Boston, MA
-
#2
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD
-
#3
University of Washington, Institute for Health Metrics and Evaluation (IHME)
Seattle, WA
-
#4
University of Oxford, Centre for Health Economics
Oxford, England
-
#5
Massachusetts General Hospital, Center for Quantitative Health
Boston, MA
